BridgeBio have demonstrably boosted the course of a innovative solution for ATTR-CM, leveraging the investigational drug. Initial clinical information suggests promising improvements for patients suffering with this https://bridgebio246588.wssblogs.com/42017241/firm-progresses-amyloidosis-therapy-using-the-drug